Seagen Inc
F:SGT
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
193.7
211.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Seagen Inc
Stock-Based Compensation
Seagen Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Seagen Inc
F:SGT
|
Stock-Based Compensation
$352.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
39%
|
CAGR 10-Years
28%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$872m
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$739.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Seagen Inc
Glance View
Seagen Inc. is a leading biotechnology company focused on developing innovative therapies for cancer treatment using its pioneering antibody-drug conjugate (ADC) technology. Founded in 1998, Seagen's mission is rooted in the belief that targeted therapies can improve the lives of cancer patients. The company has gained attention in the oncology space with its flagship products, such as Adcetris (brentuximab vedotin) and Padcev (enfortumab vedotin), which target specific cancer cells while minimizing damage to healthy tissue. This approach not only enhances efficacy but also helps in reducing side effects commonly associated with traditional chemotherapy. With a strong pipeline of investigational therapies that leverage their ADC platform, Seagen is positioned to be a transformative player in the oncology market. For investors, Seagen represents a compelling opportunity within the biotech sector, especially as demand for effective cancer treatments continues to grow. The company is actively expanding its product portfolio through strategic partnerships and collaborations, bolstering its capabilities in research and development. Financially, Seagen has demonstrated solid sales growth driven by its approved products, and it is continually working towards regulatory approvals for its pipeline candidates. As the landscape of cancer treatment evolves and personalized medicine becomes increasingly important, Seagen's innovative approach and commitment to delivering better patient outcomes make it a company to watch for those interested in the future of oncology and of the broader biotechnology market.
See Also
What is Seagen Inc's Stock-Based Compensation?
Stock-Based Compensation
352.8m
USD
Based on the financial report for Sep 30, 2023, Seagen Inc's Stock-Based Compensation amounts to 352.8m USD.
What is Seagen Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
28%
Over the last year, the Stock-Based Compensation growth was 69%. The average annual Stock-Based Compensation growth rates for Seagen Inc have been 32% over the past three years , 39% over the past five years , and 28% over the past ten years .
You don't have any saved screeners yet
